#Thinksabio latest news
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients